

Pathology of hematolymphoid system

Acute Leukemia

Histiocytic tumors

Professor Tariq Aladily
Department of Pathology
The University of Jordan
tnaladily@ju.edu.jo



School of Medicine





* Most of disorders related to WBCs are neoplastic.

ACUTE MYELOID LEUKEMIA AML

Most aggressive

- Occur at all age groups, but more common in elderly

Many Subtypes
Heterogenous, diagnosis is made by morphologic, immunophenotypic and karyotype studies

↳ Chromosomes
Prognosis depends most importantly on type of mutations (molecular and cytogenetic studies)

↳ Karyotype
Symptoms are accelerated, become significant within few weeks → cytopenia because the bone marrow is filled with blasts instead of normal cells

Symptoms are related to anemia, thrombocytopenia and neutropenia

Involvement of LN, spleen and solid organs is rare. When occurs, it is called myeloid sarcoma (acute monoblastic leukemia)

↳ Solid mass → destruction

For diagnosis we depend on:

- Morphology
- Examine the antigens
- Karyotyp: chromosomes

* Some mutations are common

So they remain in the bone marrow or in the peripheral blood



PATHOGENESIS


- Mutations in genes of transcription factors required for maturation and differentiation of myeloblasts
↳ So they do not mature
- Additional mutations in tyrosine kinase pathways (RAS)
- Epigenetic mutation is common (20%); mutation is isocitrate dehydrogenase (IDH) produces an oncometabolite that blocks enzyme of epigenome and interferes with myeloblast differentiation

← responsible for all the epigenetic mutations in all the DNA.



WHO-CLASSIFICATION OF AML

- Therapy related AML: occurs after treatment with chemo or radiotherapy *It's toxic to the stem cells*
- AML with recurrent cytogenetic mutation
↳ They are named according to the mutation. Just see the AML with Cyt inversion
- AML with myelodysplasia: occurs de novo or complicates MDS → AML with MDS
myelodysplastic syndrome
They are rare cells ← *IF the MDS is 20% of the total cells either in blood or marrow it becomes AML.*
IF less than 20% it's still in the MDS stage.
- AML-Not otherwise specified
- Diagnosis of AML: 20% blasts in peripheral blood or bone marrow (of nucleated cells)



- Morphology: large cells, high N/C ratio, fine granules in cytoplasm, fine chromatin, prominent nucleoli
 - ↳ normal mature
 - ↳ large nucleus
- Auer rods: small pink rods present in cytoplasm, represent peroxidase enzyme
 - ↳ Only seen in myeloblasts they are granules but with morphologic change (same content).
- Myeloblasts express CD34, myeloperoxidase (MPO), CD13, CD33
- Sometimes: monoblast, erythroblast, megakaryoblast
 - ↳ If it reaches >20%

* CD4: only expressed in blasts and it's negative in mature cells.

* We use the flowcytometry to check the presence of these antigens.

↳ contain many enzymes mainly myeloperoxidase

↳ immature



OUTCOME

- Generally poor, <30% responds to chemotherapy *Very poor prognosis* *There are new therapies but still promising like Isocitrate dehydrogenase Inhibitors.*
- Worse than ALL
- P53 mutation: worse outcome
- IDH inhibitors are new promising drugs



SubType of AML

ACUTE PROMYELOCYTIC LEUKEMIA

- Promyelocyt is the stage of maturation that comes after myeloblast.
- we don't find blasts \rightarrow we find malignant promyelocyte.
- Also called AML-M3
 - Maturation is arrested at promyelocyte stage
 - Leukemic cells appear similar to promyelocytes (heavy ^{positive only in blasts.} cytoplasmic granules, numerous Auer rods, negative for CD34)
 - ^{special mutations that are not seen in any other leukemias} Carry recurrent mutation: t(15;17) fusion between PML gene (chrom 15) with alpha retinoic acid receptor (RARA) on chrom 17. Chimeric fusion gene produces a protein that blocks promyelocyte maturation by inhibiting the action of retinoic acid.
 - All trans-retinoic acid (ATRA), a vitamin A analogue, overcomes this block. Effect is synergistic with arsenic trioxide (degrades oncoprotein)
 - Malignant promyelocyte secrete tissue factor, causing DIC
 - * Vitamin A is important for the maturation of leukemic cells.
 - * The mutation leads to the appearance of a chimeric protein that inhibits the usage of VIT.A for maturation.
 - * Treatment: Very large dose of VIT.A \rightarrow force the chimeric protein to detach from the receptor (RARA).
 - * VIT.A that's used is alpha trans retinoic acid \rightarrow which is a derivative with the same function.

* other treatment is Arsenic trioxide : toxic was previously used as poison.


* No Chemotherapy 2^{nd}

* patients develop DIC because the promyelocyte secrete TF. And patients die from DIC not from the cancer itself.

* They are like the blasts but with numerous granules.

* Auer Rods.

* May find 2 nuclei because it's malignant.



- APL: malignant promyelocytes show numerous cytoplasmic granules and Auer rods. The nuclei are commonly cleaved.

PRECURSOR B AND T CELL NEOPLASMS

★ Can appear in blood and bone marrow. and can appear in other tissues.

★ Lymphocytes are every where.

★ when it arise in tissues it's known as lymphoblastic lymphoma (lymphoma).

- Lymphoblastic lymphoma when occurs in solid tissue (T>B)
- Acute lymphoblastic leukemia when circulates peripheral blood and involve bone marrow (B>T)
- B-ALL is the most common childhood malignancy
 - ↳ Can occur at any age
- Neoplastic cells are lymphoblasts, the most immature lymphoid cell. Aggressive neoplasms, express CD34 and **TDT** To distinguish lymphoblasts from leukocytes.
- T-ALL is less common, presents in adolescents, involving thymus, more common in boys
- B-ALL tends to disseminate to solid organs (brain, testis, spleen)




PATHOGENESIS

- Mutations in transcription factors for genes responsible for maturation of blasts
 - In B-LL, mutation in PAX5 gene
- Mutations in RAS signaling and tyrosine kinase proteins promoting cell survival
- Most childhood B-ALL have ^{Single cell with very large number of chromosomes} hyperdiploidy (>50 chromosomes) and $t(12;21)$, involving ETV6 and TUNX1 genes, creating new transcription factor
 - Adult B-ALL exhibits $t(9;22)$ between ABL and BCR genes, similar to chronic myeloid leukemia, creating a new tyrosine kinase protein (imatinib)
 - ^{Philadelphia Chromosome was discovered firstly in Chronic myeloid leukemia.} CML
 - T-ALL shows mutation in NOTCH1 gene (70% of cases), PTEN gene (tumor suppressor) and CDKN2A (promotes cell cycle)


MORPHOLOGY OF ALL

- Blasts are large, high N/C ratio
- Chromatin is open (pale) *(higher than myeloblasts)*
- Nucleolus sometimes present
- Cytoplasm is not granular

fine
No cytoplasm can be seen



Immunophenotype



CLINICAL FEATURES

- Anemia, thrombocytopenia
- Bone pain *Common → fill with Marts*
- Lymphadenopathy and hepatosplenomegaly
- Testicular enlargement
- Mediastinal mass (T-ALL)
↳ In thymus → compression on heart and lungs
- CNS involvement *harder treatment, chemotherapy in the spinal cord*
- Damage to solid organs secondary to leukemic infiltration
↳ like brain
- Favorable prognostic factors in B-ALL: hyperdiploidy, low WBC count, age between 2-10 years
↳ better than ALL
↳ good prognosis
→ They response to chemo.
- Poor prognostic factors in B-ALL: age < 2 years, age in adolescents or adults, WBC count >100k

★ There are many types of histiocytic tumors.

★ This is the most common ↓

LANGERHANS CELL HISTIOCYTOSIS

- Neoplasm of dendritic cells

→ APC. They are similar to dendrites in nerves in case of the disease → they become large and swollen like histiocytes.

- Langerhans cells express CD1a and Langerin

- Langerin is a transmembrane protein, attached to Birbeck granules (tennis racket shape under electron microscope)
cyttoplasmic and
years before they used to use the EM for diagnosis.
Now we directly use antigens.

- Proliferating Langerhans cells appear large and vacuolated, similar to macrophages

→ They became neoplastic → that's why their shapes have changed.

- Pathogenesis: acquired mutation in serin/threonine kinase **BRAF**, leads to hyperactivity of this kinase
Seen in ① B-cell lymphoma
② LCH.

MULTISYSTEMIC LCH

☞ everywhere in the body

- Occurs mostly in children less than 2 years
- Multiple cutaneous lesion, composed of LCs
- Hepatosplenomegaly and lymphadenopathy
- Pulmonary lesions *Can also affect the heart*
- Osteolytic lesions
- Extensive bone marrow infiltration leads to pancytopenia
- Treated with chemotherapy



UNISYSTEM LCH

- AKA eosinophilic granuloma
other name used in medicine
or my name
- Affects a single organ, most commonly bone, then skin, lung, stomach
- Can be unifocal or multifocal
- Unifocal is commonly asymptomatic, can cause pain
- Multifocal unisystem disease presents in children, commonly affects
base of the skull calvaria bone, extends to pituitary gland causing diabetes insipidus, exophthalmous (Hand- Schuller-Christian triad).
busting of the orbit
- Proliferating LCs are admixed with numerous eosinophils, lymphocytes, plasma cells and neutrophils
they all participate in the mass formation
- Treatment: unifocal: surgical excision, multifocal: chemotherapy, sometimes spontaneous regression